A Study Comparing Different Stem Cell Mobilization Approaches in Patients with Multiple Myeloma

Full Title
A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients with Symptomatic Multiple Myeloma

Stem cell transplantation is a common approach to treating multiple myeloma. A patient’s own stem cells are collected and stored to be given back after chemotherapy, as a means of helping to rebuild the patient’s blood-forming system. The process of getting the stem cells to move from the bone marrow to the bloodstream for collection is called “stem cell mobilization.

Stem cells are usually mobilized using drugs called G-CSF and cyclophosphamide. Studies have suggested that bortezomib, an anticancer drug used to treat multiple myeloma, may also enhance stem cell mobilization.

In this study, researchers are comparing different stem cell mobilization approaches to see if adding bortezomib makes the process more effective. Patients will be randomly assigned receive both high-dose cyclophosphamide and G-CSF, either with or without bortezomib. Bortezomib and cyclophosphamide are given intravenously (by vein), while G-CSF is injected under the skin.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have previously treated multiple myeloma which is causing symptoms.
  • Patients must be considered candidates for possible stem cell transplantation. Those who have already had a stem cell transplant may not participate.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Heather Landau at 212-639-8808.

Hematology: Multiple Myeloma
Related Diseases